IRAK1 expression is increased in breast cancer paclitaxel-resistant cell lines, an IRAK1 inhibitor reverses paclitaxel resistance in triple-negative breast cancer, and IRAK1 is also a potential therapeutic target for paclitaxel resistance in nasopharyngeal carcinoma (39). The gene discussed is IRAK1; the disease is triple-negative breast carcinoma.